Unlike gradual weight loss through lifestyle changes alone, the efficiency of GLP-1 medications means patients reach their goal weight before their skin has time to adjust
Among these, TRElimiting the daily eating window to 412 h, typically with 12-h overnight fastinghas gained popularity due to its practical feasibility and better adherence
Central obesity increases risk of falling through postural instability from an anterior shift of the center of gravity
Tyr 10 Positions 10, 12, 13, and 14 of exenatide (full GLP-1R agonist) are different from those of GLP-1, suggesting that these residues are unimportant to GLP-1
PMID: 1313797
Therefore, the development of an oral delivery strategy for peptide GLP-1R agonists is expected to reduce these adverse effects and improve patient compliance and quality of life (Borner et al., 2020